Key result
Impella 5.0 provides full cardiac support and is linked to fewer vascular complications in cardiogenic shock.
Why the study?
Does Impella 5.0 provide effective and safe support in patients with cardiogenic shock?
Systematic Review
Does Impella 5.0 provide effective and safe support in patients with cardiogenic shock?
Impella 5.0 appears to offer effective cardiac support with a favorable vascular safety profile in cardiogenic shock, though large-scale randomized trials are still needed.
Impella 5.0 may support full hemodynamics in cardiogenic shock with fewer vascular complications; leaves open definitive efficacy pending large RCTs.
Impella 5.0 provides a full cardiac support, it is associated with a lower rate of vascular complications, it represents a valuable bridge-to-decision and allows for resolution of intercurrent clinical conditions. As available data suggest Impella 5.0 good performance in CS of various etiologies, more solid evidence will come from much-needed large-scale all-comer registries and prospective multicenter randomized trials.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a systematic review in cardiogenic shock. Impella 5.0 was evaluated. Impella 5.0 provides full cardiac support and is associated with a lower rate of vascular complications in cardiogenic shock, though large-scale randomized trials are needed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: